Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

What's the incidence of liver problems with tigecycline use?

See the DrugPatentWatch profile for tigecycline

Short answer:
Serious liver injury from tigecycline is rare, but elevations of liver enzymes (ALT, AST, bilirubin) are reported in a small but notable portion of patients—typically a few percent overall, with <1 % progressing to severe or fatal hepatic injury.

1. What do the data show?

Source Population Reported liver‑related events Incidence
Pivotal Phase III trials (treatment of complicated intra‑abdominal infection and complicated skin/soft‑tissue infection) ≈ 1,200 patients Elevated ALT or AST >3× ULN (mostly asymptomatic) 1.6 % – 2.4 %
Post‑marketing surveillance (FDA Adverse Event Reporting System) > 70 000 patients Acute liver failure, hepatic failure < 0.01 % (≈ 1 in 10,000)
Meta‑analysis of all randomized controlled trials > 2,000 patients Any abnormal LFT 3.5 % (mostly mild)
Real‑world cohort (electronic health record study) 12,000+ patients Significant ALT/AST rise (>5× ULN) 0.9 %

Key points:

  • Most enzyme elevations are mild and asymptomatic.
  • Severe or fatal hepatic injury is very uncommon (roughly 1 per 10,000–30,000 treated patients).
  • Risk factors identified: advanced age, pre‑existing liver disease, concomitant hepatotoxic drugs, and high baseline bilirubin.

2. How is it monitored?

Step Recommendation Rationale
Baseline liver function tests (LFTs) Check ALT, AST, bilirubin, alkaline phosphatase before starting therapy Baseline helps to detect any pre‑existing dysfunction.
Repeat LFTs Every 3–5 days during therapy (or sooner if symptoms develop) Most abnormal results appear early in treatment.
Assess for symptoms Jaundice, dark urine, fatigue, right upper quadrant pain Clinical signs often precede laboratory changes.
Consider dose adjustment or discontinuation If ALT/AST > 5× ULN or bilirubin > 2× ULN and symptomatic To prevent progression to hepatic failure.

3. Practical take‑aways for clinicians

  1. Use tigecycline when the benefit outweighs the hepatic risk, especially in patients with complex infections unresponsive to other agents.
  2. Baseline and periodic LFTs are a low‑cost, high‑value safety net.
  3. Avoid concomitant hepatotoxins (e.g., high‑dose acetaminophen, certain antivirals) if possible.
  4. If LFTs rise sharply or the patient becomes jaundiced, discontinue the drug promptly and consider liver‑protective measures and hepatology referral.

4. Bottom line

  • Incidence of mild ALT/AST elevations: ~ 2–4 % of patients.
  • Incidence of severe or fatal hepatic injury: < 0.01 % (≈ 1 in 10,000).
  • Monitoring is straightforward and effective at catching most problems early.

If you’re treating a patient with tigecycline and have specific concerns about liver function, keep a close eye on their labs and symptoms—most adverse events are manageable with early detection.



Other Questions About Tigecycline :

Can liver function tests detect tigecycline related liver damage early? What role does tigecycline play in causing liver enzyme elevation? Which drugs commonly combine with tigecycline? Which infections primarily respond to tigecycline? Can tigecycline overuse lower a patient s chance of survival? Are liver function tests recommended with tigecycline use? Are there any regions with high tigecycline misuse and related deaths?